secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioAtla, Inc. (BCAB)
CIK:        0001826892
Form:       8-K
Filed at:   2026-03-02T23:59:59+00:00
Accession:  0001539497-26-000812
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 7.01, 2.05, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioAtla initiates strategic review, cuts 70% workforce; CFO replaced; cash ~$7.1M
--------------------------------------------------------------------------------

- Workforce reduced ~70%; severance costs estimated $0.5-0.6M; committed Feb 24, 2026.
- CFO Richard Waldron departs March 2; succeeded by Chief Accounting Officer Chris Vasquez.
- Formal strategic review launched to monetize assets; Tungsten Advisors engaged as advisor.
- Preliminary cash and cash equivalents $7.1M as of Dec 31, 2025; no PPA amounts outstanding.
- Nasdaq delisting review ongoing; $40M SPV transaction with Inversagen AI not yet closed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826892/000153949726000812/0001539497-26-000812-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826892/000153949726000812/n5620_8k.htm
  HTML page:      https://secwatch.observer/filing/0001539497-26-000812

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer